Alefacept in Subjects With Steroid-Refractory Chronic Graft-versus-Host Disease

* During the first week of treatment, participants will receive 2 doses of Alefacept intravenously (Day 1 and Day 4). During weeks 2-12, Alefacept will be given subcutaneously once weekly. * On weeks 1, 2 and every other week through Week 12 of study treatment, participants will have a physical exam, blood tests, and be asked general health and specific questions about any problems they may be having. * Every other week, participants will be asked to complete a questionnaire about their physical symptoms, activity level and emotional well being.